Target intelligence / Profile preview

KRAS promoter G-quadruplex DNA (KRAS G4) (KRAS G4)

Target
KRAS G4
Molecular classification
Nucleic acid, Non-canonical DNA structure, G-quadruplex
01

Overview

The KRAS promoter G-quadruplex DNA is a non-canonical secondary structure formed within the guanine-rich nuclease hypersensitive element (NHE) of the KRAS gene promoter (Cogoi & Xodo, 2006). This structure serves as a molecular switch that regulates the transcription of the KRAS oncogene, a key driver in many human cancers including pancreatic, colorectal, and lung carcinomas (Brooks et al., 2010). In its folded state, the G-quadruplex physically impedes the transcriptional machinery, thereby reducing the production of KRAS mRNA and protein (Kuo et al., 2015). Because the KRAS protein has historically been considered difficult to target directly due to its smooth surface and high affinity for GTP, targeting the G-quadruplex structure in its promoter offers an alternative therapeutic strategy to downregulate its expression (Ou et al., 2014). Small-molecule ligands, such as TMPyP4 and various indoloalkane derivatives, have been developed to bind and stabilize this structure, effectively silencing the gene in experimental models (Cogoi & Xodo, 2006). However, achieving high selectivity for the KRAS G-quadruplex over other genomic G-quadruplexes remains a significant challenge in clinical development (Brooks et al., 2010).

Other names
KRAS G4KRAS promoter G-quadruplexKRAS nuclease hypersensitive elementKRAS NHE
02

Mechanism of action

Small molecule ligands bind to and stabilize the G-quadruplex structure within the KRAS promoter region, which physically obstructs the transcriptional machinery and reduces the expression of the KRAS protein.

03

Biological functions

Transcription regulationGene expression control
04

Disease associations

CancerPancreatic cancerColorectal cancerNon-small cell lung cancer
05

Safety considerations

Potential off-target binding to other genomic G-quadruplexesSystemic toxicity of G4-stabilizing ligandsChallenges in achieving high selectivity for the KRAS G4 over other oncogenic G4s
06

Interacting drugs

TMPyP4

4 more in the full profile.

07

Biomarkers

KRAS mRNA expression levelsKRAS protein levelsKRAS mutation status

Beyond the preview

Go deeper on KRAS promoter G-quadruplex DNA (KRAS G4) (KRAS G4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on KRAS promoter G-quadruplex DNA (KRAS G4) (KRAS G4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call